Presentation is loading. Please wait.

Presentation is loading. Please wait.

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation  Junya Nakade,

Published byErika Bogaert Modified over 5 years ago

Similar presentations

Presentation on theme: "Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation  Junya Nakade,"— Presentation transcript:

1 Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation  Junya Nakade, MS, Shinji Takeuchi, MD, PhD, Takayuki Nakagawa, MS, Daisuke Ishikawa, MD, Takako Sano, PhD, Shigeki Nanjo, MD, Tadaaki Yamada, MD, PhD, Hiromichi Ebi, MD, PhD, Lu Zhao, MS, Kazuo Yasumoto, MD, PhD, Kunio Matsumoto, PhD, Kazuhiko Yonekura, PhD, Seiji Yano, MD, PhD  Journal of Thoracic Oncology  Volume 9, Issue 6, Pages (June 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Combined use of crizotinib or TAS-115 with erlotinib reverses resistance to EGFR-TKI induced by exogenous HGF. A and B, PC-9 cells were incubated with or without erlotinib or crizotinib and TAS-115 in the presence or absence of HGF (20 ng/ml) for 72 hours. Cell viability was determined by MTT assay. Bars show SD. The data shown are representative of five independent experiments with similar results. EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR-tyrosine kinase inhibitor; HGF, hepatocyte growth factor; MTT, Thiazolyl Blue Tetrazolium Bromide. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Combined use of crizotinib or TAS-115 with erlotinib reverses resistance to EGFR-TKI induced by endogenous HGF. A, PC-9/Vec and PC-9/HGF cells were incubated with or without erlotinib for 72 hours. Cell viability was determined by MTT assay. Bars show SD. B and D, PC-9/Vec and PC-9/HGF cells were treated with crizotinib or TAS-115 for 72 hours. C–G, PC-9/Vec and PC-9/HGF cells were incubated with or without erlotinib (0.3 μmol/liter) with or without crizotinib (0.3 μmol/liter) and TAS-115 (1.0 μmol/liter) for 72 hours. The data shown are from three independent experiments with similar results. H and I, PC-9/HGF cells were incubated with TAS-115 (1.0 μmol/liter) or crizotinib (0.3 μmol/liter) and/or erlotinib (0.3 μmol/liter) for 1 hour. Thereafter, cell lysates were harvested, and phosphorylation of the indicated proteins was determined by Western blot analysis. EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR-tyrosine kinase inhibitor; HGF, hepatocyte growth factor; MTT, thiazolyl blue tetrazolium bromide. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Crizotinib and TAS-115 inhibits VEGF production by cancer cells and endothelial proliferation. A and B, Tumor cells were incubated with or without HGF (50 ng/ml) in the presence of different concentrations of crizotinib or TAS-115 for 48 hours. Thereafter, supernatants were harvested, and the number of tumor cells was counted. VEGF concentration in the supernatants was determined by ELISA. VEGF levels corrected by the tumor cell number are shown. C and D, HMVECs were incubated in RPMI-1640 medium with 10% FBS (control) or RPMI-1640 medium with 10% FBS in the presence or absence of VEGF (50 ng/ml) with different concentrations of TAS-115, crizotinib, or bevacizumab for 72 hours. Thereafter, cell viability was determined by MTT assay. Bars show SD. The data shown are from three independent experiments with similar results. VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; ELISA, enzyme-linked immunosorbent assay; HMVECs, human dermal microvascular endothelial cells; FBS, fetal bovine serum; MTT, thiazolyl blue tetrazolium bromide. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Treatment with erlotinib plus TAS-115 inhibits angiogenesis in PC-9/HGF tumors in vivo. Nude mice bearing PC-9/Vec or PC-9/HGF tumors (approximately 100 mm3 in size) were administered erlotinib and/or crizotinib and/or TAS-115 orally, once daily for 4 days, and/or bevacizumab intraperitoneally only once. A, The mice were killed on day 4, and the tumors were harvested. B, Numbers of tumor vessels (mean ± SE) determined by CD31 immunohistochemical staining are shown for groups containing five mice each. Representative graphs are shown. The data shown are representative of two independent experiments with similar results. HGF, hepatocyte growth factor. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Treatment with erlotinib plus TAS-115 inhibits the growth of PC-9/HGF tumors in vivo. A and B, Nude mice bearing PC-9/Vec or PC-9/HGF tumors (approximately 100 mm3 in size) were administered erlotinib and/or crizotinib and/or TAS-115 orally once daily and/or bevacizumab intraperitoneally once a week. Tumor volume was measured using calipers. Mean ± SE tumor volumes on day 39 are shown for groups containing five mice each. The data shown are representative of two independent experiments with similar results. HGF, hepatocyte growth factor. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 Treatment with erlotinib plus TAS-115 most strongly prevented the regrowth of PC-9/HGF tumors even after cessation of treatment. A, Nude mice bearing PC-9/HGF tumors were treated as described in Figure 5 until day 39. Thereafter, treatment was terminated, and tumor volume was measured until day 49. B, The mice were killed on day 49, and tumors were harvested. Tumor vessels and apoptotic cells were determined by CD31 immunohistochemical and TUNEL staining, respectively. Asterisk indicates P < HGF, hepatocyte growth factor; TUNEL, terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate-biotin nick end-labeling. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation  Junya Nakade,"

Similar presentations

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy  Flavia.

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy  Flavia.
Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 
Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T- Cell Depletion in a Murine Mesothelioma Model  Licun Wu, MD, Zhihong.

Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T- Cell Depletion in a Murine Mesothelioma Model  Licun Wu, MD, Zhihong.
Drug concentration (μM)

Drug concentration (μM)
Molecular Therapy - Oncolytics

Molecular Therapy - Oncolytics
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,
NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer  Koichi Azuma, MD, PhD, Akihiko Kawahara, PhD, Satoshi.

NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer  Koichi Azuma, MD, PhD, Akihiko Kawahara, PhD, Satoshi.
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis  Dao M Nguyen, MD, Dominique.

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis  Dao M Nguyen, MD, Dominique.
An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb.

An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb.
Shear stress-stimulated endothelial cells induce smooth muscle cell chemotaxis via platelet-derived growth factor-BB and interleukin-1α  Alan Dardik,

Shear stress-stimulated endothelial cells induce smooth muscle cell chemotaxis via platelet-derived growth factor-BB and interleukin-1α  Alan Dardik,
Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene  Madoka Kimura,

Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene  Madoka Kimura,
Volume 134, Issue 7, Pages (June 2008)

Volume 134, Issue 7, Pages (June 2008)

Similar presentations

Ads by Google